152 related articles for article (PubMed ID: 34924268)
41. Cross-Sectional Study of four Serological Bone Turnover Markers for the Risk Assessment of Medication-Related Osteonecrosis of the Jaw.
Peisker A; Raschke GF; Fahmy MD; Guentsch A; Roshanghias K; König KC; Schultze-Mosgau S
J Craniofac Surg; 2018 Mar; 29(2):e137-e140. PubMed ID: 29215447
[TBL] [Abstract][Full Text] [Related]
42. Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.
Soares AL; Simon S; Gebrim LH; Nazário ACP; Lazaretti-Castro M
Support Care Cancer; 2020 May; 28(5):2265-2271. PubMed ID: 31468192
[TBL] [Abstract][Full Text] [Related]
43. Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a patient receiving Bemcentinib-a case report.
Bumm CV; Folwaczny M; Wölfle UC
Oral Maxillofac Surg; 2020 Sep; 24(3):353-358. PubMed ID: 32440898
[TBL] [Abstract][Full Text] [Related]
44. Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer.
Ueda N; Aoki K; Shimotsuji H; Nakashima C; Kawakami M; Imai Y; Kirita T
J Bone Miner Metab; 2021 Jul; 39(4):623-630. PubMed ID: 33420576
[TBL] [Abstract][Full Text] [Related]
45. Autologous platelet concentrates in treatment of medication related osteonecrosis of the jaw.
Rusilas H; Balčiūnaitė A; Žilinskas J
Stomatologija; 2020; 22(1):23-27. PubMed ID: 32706343
[TBL] [Abstract][Full Text] [Related]
46. Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study.
Zhou Y; Yu Y; Shi Y; Li M; Yang C; Wang S
Biomed Res Int; 2020; 2020():5847429. PubMed ID: 33123580
[TBL] [Abstract][Full Text] [Related]
47. Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis.
Kuroshima S; Sasaki M; Murata H; Sawase T
Gerodontology; 2019 Dec; 36(4):313-324. PubMed ID: 31373407
[TBL] [Abstract][Full Text] [Related]
48. [Diagnosis and treatment of medication-related osteonecrosis of the jaws from an oncologist's perspectives].
Yuan P
Zhonghua Kou Qiang Yi Xue Za Zhi; 2021 May; 56(5):415-420. PubMed ID: 33904274
[TBL] [Abstract][Full Text] [Related]
49. Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis.
Devlin H; Greenwall-Cohen J; Benton J; Goodwin TL; Littlewood A; Horner K
Br Dent J; 2018 Jan; 224(1):26-31. PubMed ID: 29192692
[TBL] [Abstract][Full Text] [Related]
50. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
51. Assessing the Potential Role of Artificial Intelligence in Medication-Related Osteonecrosis of the Jaw Information Sharing.
Çoban E; Altay B
J Oral Maxillofac Surg; 2024 Jun; 82(6):699-705. PubMed ID: 38527729
[TBL] [Abstract][Full Text] [Related]
52. Mechanism, prevention, and treatment for medication-related osteonecrosis of the jaws.
Pan J; Liu JY
Hua Xi Kou Qiang Yi Xue Za Zhi; 2021 Jun; 39(3):245-254. PubMed ID: 34041871
[TBL] [Abstract][Full Text] [Related]
53. Osteonecrosis of the jaws: a 14-year retrospective survey of hospital admissions.
McGowan K; Ivanovski S; Acton C
Aust Dent J; 2018 Jun; 63(2):202-207. PubMed ID: 29432652
[TBL] [Abstract][Full Text] [Related]
54. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
[TBL] [Abstract][Full Text] [Related]
55. "Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review.
Khominsky A; Lim M
Aust Dent J; 2018 Dec; 63(4):441-454. PubMed ID: 30144095
[TBL] [Abstract][Full Text] [Related]
56. Periosteal reaction of medication-related osteonecrosis of the jaw (MRONJ): clinical significance and changes during conservative therapy.
Soutome S; Otsuru M; Hayashida S; Yanamoto S; Sasaki M; Takagi Y; Sumi M; Kojima Y; Sawada S; Iwai H; Umeda M; Saito T
Support Care Cancer; 2021 Nov; 29(11):6361-6368. PubMed ID: 33884506
[TBL] [Abstract][Full Text] [Related]
57. Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy.
Traboulsi-Garet B; Jorba-García A; Camps-Font O; Alves FA; Figueiredo R; Valmaseda-Castellón E
Clin Oral Investig; 2022 Mar; 26(3):2371-2382. PubMed ID: 35124731
[TBL] [Abstract][Full Text] [Related]
58. Medication-related osteonecrosis of the maxilla: Prognosis of oral surgery combined with endoscopic sinus surgery.
Park JH; Alfafara AM; Park YL; Bae JH; Kim SJ
Oral Dis; 2021 May; 27(4):962-969. PubMed ID: 32810362
[TBL] [Abstract][Full Text] [Related]
59. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up.
Nisi M; Karapetsa D; Gennai S; Ramaglia L; Graziani F; Gabriele M
J Craniomaxillofac Surg; 2018 Jul; 46(7):1153-1158. PubMed ID: 29802059
[TBL] [Abstract][Full Text] [Related]
60. Weak evidence for the management of medication-related osteonecrosis of the jaw: An overview of systematic reviews and meta-analyses.
Moraschini V; Calasans-Maia MD; Louro RS; Arantes EBR; Calasans-Maia JA
J Oral Pathol Med; 2021 Jan; 50(1):10-21. PubMed ID: 32589782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
